CoChat

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial

Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C. I., Steg, P. G., Davidson, J., Ohman, P., Price, D. L., Frederich, B., Udell, J. A., Braunwald, E., Bhatt, D. L. · 2013 · Diabetes/Metabolism Research and Reviews
Cited by 52

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background and aims: SAVOR‐TIMI 53 was designed to study the effects of the DPP‐4 inhibitor saxagliptin on cardiovascular outcomes in high risk type 2 diabetes patients with diverse levels of diabetes control and background anti‐diabetic drugs. The goal of this article is to describe the baseline characteristics of this hypothesis driven study. Materials and methods: A total of 16 496 diabetic patients from North America (31.9%), Western Europe (26.0%), Eastern Europe (17.3%), Latin America (16.4%) and Asia (8.3%), with either established cardiovascular disease (78.3%) or with ≥two additional cardiovascular risk factors (21.7%) were randomised to saxagliptin or placebo. Biomarkers of inflammation and insulin resistance were taken at baseline and 2 years later in order to correlate saxagliptin effect on cardiovascular outcome to its effect on inflammation and insulin resistance. Results: Mean [+/−standard deviation (SD)] age was 65.0 (+/−8.6) years, 66.9% were male, body mass index was 31.2 kg/m 2 (+/−5.6), mean diabetes duration was 11.9 years (+/−8.9) and the mean HbA 1c 8.0% (+/−1.4%). HbA 1c < 7% was most prevalent among North Americans (30.8%) and least among Asians (15.1%), whereas HbA 1c > 9% was 30.7% in Latin America 27.0% in Asia and 15.1% in North America. Diabetic retinopathy was reported in 12.3% of patients, nephropathy in 17.7% and amputation in 2.5%. Diabetic treatments categories were as follows: no medication (5.4%), 1 oral anti‐diabetic drug (OAD) (25.0%), ≥2 OAD (27.7%) and/or insulin (40.9%). The prevalence of micro‐albuminuria was twice as high among insulin users compared with users of ≥2 OAD. Baseline statin use (78.3% overall) varied by region. Conclusion: The SAVOR‐TIMI 53 patient population, with differing background diabetes control and anti‐diabetic treatment, provides global representation of diabetic patients with established cardiovascular disease or at high risk for cardiovascular disease and is well‐positioned to determine the effect of saxagliptin on cardiovascular events. Copyright © 2013 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2413

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 52

Metadata

Authors
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C. I., Steg, P. G., Davidson, J., Ohman, P., Price, D. L., Frederich, B., Udell, J. A., Braunwald, E., & Bhatt, D. L.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2013-05-21
Volume
29
Issue
5
Pages
417-426
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1494561942
Cited by
52
References
15
FWCI
6.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.